The Multiple Myeloma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Updating the NCCN guidelines for the diagnosis and treatment of MGUS and SMM

During the National Comprehensive Cancer Network (NCCN) 2021 Annual Conference, the Mutiple Myeloma Hub spoke to Timothy M. Schmidt, University of Wisconsin-Madison, Madison, US. We asked about updates to the NCCN guidelines for the diagnosis and treatment of monoclonal gammopathy of unknown significance (MGUS) and smoldering multiple myeloma (SMM).

Updating the NCCN guidelines for the diagnosis and treatment of MGUS and SMM

For MGUS, Schmidt discusses the addition of the new term, 'monoclonal gammopathy of neurological significance', for patients with IgM polyneuropathy. For SMM, Schmidt highlights the use of the 20:2:20 risk stratification criteria to identify high-risk SMM and discusses treatment options for this group of patients.


Share: